 "Panacea Biotech Q1 net loss at Rs 61 cr")
The company had reported net loss of Rs 65.97 crore in the April-June quarter of the last fiscal.
Panacea Biotech's net sales in Q1, 2013-14 were at Rs 104.46 crore, an increase of 25.70% as against Rs 83.10 crore in the year-ago period, the company said in BSE filing.
Also Read
Revenue from vaccines in Q1 grew over four fold at Rs 28.04 crore, and revenue from formulations was at Rs 81.58 crore down 0.22%.
Overall expenses in the quarter were at Rs 145.72 crore, an increase of 14.43% compared with Rs 127.34 crore in the corresponding period last year.
Panacea Biotech scrip closed at Rs 94.50, up 3%, on the BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%